A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINâ„¢, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINâ„¢, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
Inclusion Criteria:
Exclusion Criteria:
Fort Meyers, Florida, United States
Layfayette, Indiana, United States
Layfayette, Louisiana, United States
Kundratstrasse 3, State of Vienna, Austria
Kundratstrasse 3, Austria
La Roche S YON, France
Lyttelton Manor, South Africa, South Africa
Hospitalet de Llobregat(barcel, Catalonia, Spain
Hospitalet de Llobregat(Barcel, Spain
Nakhonratchasima, Naimuang, Thailand
Rachathewi, Thailand